Clinical Trial Update: Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial is testing gefitinib with PEG-interferon alfa-2a for unresectable or metastatic skin cancer; the status and results are not disclosed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-melanoma Skin Cancer

Drugs mentioned

• Gefitinib (Gefitinib)
• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: University of California, San Diego | Conditions: Non-melanomatous Skin Cancer | Phase 1, Phase 2 | Status: UNKNOWN